VOR BIOPHARMA INC (VOR) Stock Price, Quote, News and Overview
NASDAQ:VOR - Nasdaq - US9290331084 - Common Stock - Currency: USD
VOR Quote, Performance and Key Statistics
2.07
0 (0%)
The current stock price of VOR is 2.07 USD. In the past month the price decreased by -17.2%. In the past year, price increased by 152.44%.
VOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.7 | 349.84B | ||
| AMGN | AMGEN INC | 13.22 | 154.98B | ||
| GILD | GILEAD SCIENCES INC | 15.43 | 148.54B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.64 | 94.13B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 60.79B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.23B | ||
| ARGX | ARGENX SE - ADR | 71.39 | 40.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.5 | 31.19B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.84B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.28B | ||
| INSM | INSMED INC | N/A | 20.78B | ||
| NTRA | NATERA INC | N/A | 20.75B |
Related stock screener links
About VOR
Company Profile
Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 159 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidates include tremtelectogene empogeditemcel (trem-cel), for the treatment of acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II multicenter, open-label, first-in-human study of trem-cel in patients with AML. Its other clinical trial and pipeline products are VCAR33 / VBP301, Trem-cel+VCAR33 Treatment, System CD33-CLL1 Treatment System, and VADC45.
Company Info
VOR BIOPHARMA INC
100 Cambridgepark Drive, Suite 101
Cambridge MASSACHUSETTS US
Employees: 159
Phone: 16176556580
VOR BIOPHARMA INC / VOR FAQ
What is the stock price of VOR BIOPHARMA INC today?
The current stock price of VOR is 2.07 USD.
What is the ticker symbol for VOR BIOPHARMA INC stock?
The exchange symbol of VOR BIOPHARMA INC is VOR and it is listed on the Nasdaq exchange.
On which exchange is VOR stock listed?
VOR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VOR BIOPHARMA INC stock?
9 analysts have analysed VOR and the average price target is 1.2 USD. This implies a price decrease of -42.1% is expected in the next year compared to the current price of 2.07. Check the VOR BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VOR BIOPHARMA INC worth?
VOR BIOPHARMA INC (VOR) has a market capitalization of 258.67M USD. This makes VOR a Micro Cap stock.
How many employees does VOR BIOPHARMA INC have?
VOR BIOPHARMA INC (VOR) currently has 159 employees.
What are the support and resistance levels for VOR BIOPHARMA INC (VOR) stock?
VOR BIOPHARMA INC (VOR) has a support level at 2.06 and a resistance level at 2.17. Check the full technical report for a detailed analysis of VOR support and resistance levels.
Should I buy VOR BIOPHARMA INC (VOR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VOR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VOR, evaluating the profitability, health, valuation and growth aspects
- VOR BIOPHARMA INC (VOR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VOR BIOPHARMA INC (VOR) Sales and EPS estimates to see what analysts future expectations are.
- VOR BIOPHARMA INC (VOR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VOR BIOPHARMA INC (VOR) Insider and Institutional Ownership to learn about the owners and their transactions.
- VOR BIOPHARMA INC (VOR) Stock Chart to make your own analysis
- VOR BIOPHARMA INC (VOR) Latest news and press-releases to stay up to date.
Does VOR BIOPHARMA INC (VOR) stock pay dividends?
VOR does not pay a dividend.
When does VOR BIOPHARMA INC (VOR) report earnings?
VOR BIOPHARMA INC (VOR) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of VOR BIOPHARMA INC (VOR)?
VOR BIOPHARMA INC (VOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).
What is the Short Interest ratio of VOR BIOPHARMA INC (VOR) stock?
The outstanding short interest for VOR BIOPHARMA INC (VOR) is 20.19% of its float. Check the ownership tab for more information on the VOR short interest.
VOR Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VOR. When comparing the yearly performance of all stocks, VOR is one of the better performing stocks in the market, outperforming 99.75% of all stocks.
VOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VOR. VOR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VOR Financial Highlights
Over the last trailing twelve months VOR reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS increased by 15.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -108.49% | ||
| ROE | -179.5% | ||
| Debt/Equity | 0 |
VOR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 71% to VOR. The Buy consensus is the average rating of analysts ratings from 9 analysts.